Graham presented his findings in France Aug. 25, but already had encountered the resistance from supervisors Dr David Graham The controversy grew Friday when Grassley asked the New Jersey manufacturer, among other things, about an e-mail provided by The FDA safety officer in charge of the report in which a Merck official complained that the Food and Drug Administration's had not lived up to a prior agreement to alert Merck's before releasing any negative information about its products.